Nitto BioPharma
A biopharmaceutical company focused on nucleic acid drug delivery technologies. Develops lipid- and polymer-based delivery platforms, nucleic acid design and chemical modification capabilities, and provides program development, partnering and licensing services for translational development of genetic medicines.
Industries
Nr. of Employees
medium (51-250)
Products
Lipid-based delivery platform
A platform for delivering nucleic acid therapeutics using optimized lipid formulations and LNP compositions.
Polymer-based delivery platform
Polymer chemistry-based delivery systems for oligonucleotides and genetic medicines.
Proprietary lipid chemistries
A diverse library of lipid families used for formulation screening and optimization of delivery vehicles.
NBF-006
NBF-006 is a novel lyophilized lipid nanoparticle (LNP) formulation which delivers encapsulated small interfering ribonucleic acid (siRNA) active pharmaceutical ingredient designed to inhibit the expression of glutathione-S-transferase P (GST-Pi) to tumors.
Lipid-based delivery platform
A platform for delivering nucleic acid therapeutics using optimized lipid formulations and LNP compositions.
Polymer-based delivery platform
Polymer chemistry-based delivery systems for oligonucleotides and genetic medicines.
Proprietary lipid chemistries
A diverse library of lipid families used for formulation screening and optimization of delivery vehicles.
NBF-006
NBF-006 is a novel lyophilized lipid nanoparticle (LNP) formulation which delivers encapsulated small interfering ribonucleic acid (siRNA) active pharmaceutical ingredient designed to inhibit the expression of glutathione-S-transferase P (GST-Pi) to tumors.
Services
Licensing of delivery technologies and collaborative development partnerships for advancing genetic medicine programs.
Support for translating delivery technologies into preclinical and early-stage development programs and enabling progression toward clinical development.
Licensing of delivery technologies and collaborative development partnerships for advancing genetic medicine programs.
Support for translating delivery technologies into preclinical and early-stage development programs and enabling progression toward clinical development.
Expertise Areas
- Nucleic acid drug delivery
- Lipid nanoparticle formulation
- Polymeric delivery systems
- RNAi and siRNA therapeutics
Key Technologies
- Lipid nanoparticles (LNPs)
- Polymer-based delivery systems
- siRNA / RNAi therapeutics
- Nucleic acid chemical modification
News & Updates
Conference participation; May 17–19, 2025, Manchester Grand Hyatt San Diego, San Diego.
Conference participation; June 16–19, 2025, Boston Convention & Exhibition Center, Boston, MA.
Conference participation; Sept. 10–11, 2025, Thomas M. Menino Convention & Exhibition Center, Boston, MA.
Conference participation; Sept. 29–Oct. 1, 2025, Wyndham Boston Beacon Hill, Boston, MA.
Conference participation; Oct. 7–10, 2025, FIBES, Palacio de Exposiciones y Congresos, Seville, Spain.
Conference participation; Oct. 8–10, 2025, PACIFICO Yokohama, Yokohama, Japan.
Conference participation; May 17–19, 2025, Manchester Grand Hyatt San Diego, San Diego.
Conference participation; June 16–19, 2025, Boston Convention & Exhibition Center, Boston, MA.
Conference participation; Sept. 10–11, 2025, Thomas M. Menino Convention & Exhibition Center, Boston, MA.
Conference participation; Sept. 29–Oct. 1, 2025, Wyndham Boston Beacon Hill, Boston, MA.
Conference participation; Oct. 7–10, 2025, FIBES, Palacio de Exposiciones y Congresos, Seville, Spain.
Conference participation; Oct. 8–10, 2025, PACIFICO Yokohama, Yokohama, Japan.